Abstract

ADVANCES IN NANOPARTICLE MEDIATED DRUG DELIVERY FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE MANAGEMENT

K. Aparna*, Y. Hemalatha, T. Sri Saranya, N. Tejaswi, Dr. M. Tabitha Sharon,
Dr. K. Padmalatha

ABSTRACT

Chronic inflammatory respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) pose a significant global fitness burden. It is presenting significant mortality and morbidity.[2,3] Despite the availability of inhaled bronchodilators, corticosteroids, and biologics, a significant portion of patients still have suboptimal disease management due to poor drug deposition, quick pulmonary clearance, systemic harmful consequences, and limited ability to target disease-specific inflammatory pathways.[1,5] It compromises the therapeutic outcomes. By facilitating focused pulmonary transport, sustained drug release, improved cell uptake, and reduced systemic toxicity,[5,6] nanoparticle-mediated drug transport structures have emerged as a promising approach to overcome these obstacles. This summary provides a thorough and significant analysis of the latest developments in drug delivery systems based on nanoparticles for the treatment of allergies and COPD. The physicochemical properties, drug-loading potential, and pulmonary transport performance of various nanoparticles including polymeric, lipid-based, inorganic, and hybrid structures are discussed.[6-10] Along with protection, toxicity, and regulatory issues, preclinical and emerging medical evidence supporting their therapeutic potential is analyzed.[19,20] We highlight design strategies, biological carriers to pulmonary delivery, inhalation devices, safety challenges, and future prospects for clinical translation.[14-18] Finally, future perspectives on targeted and ingenious nanocarriers for precision breathing drugs are discussed.

Keywords: Asthma, COPD, Nanoparticles, Pulmonary drug delivery, Inhalation therapy, Nanomedicine